Lung Cancers Prompt Pfizer To Revise Exubera Label

Law360, New York (April 9, 2008, 12:00 AM EDT) -- Pfizer Inc. said Wednesday that reviews of clinical trial data showed an increase in lung cancer cases in patients who used the inhaled insulin treatment Exubera, leading the drugmaker to update the warning label on the diabetes medication.

The company said there were too few cases to determine whether the lung cancer was directly related to Exubera use but noted that all new cases of lung cancer were observed in patients who had a history of smoking.

The update to the label, Pfizer said, is based...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.